Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
Prolonged exposure to temozolomide (TMZ) could improve clinical outcomes in recurrent glioblastoma multiforme (GBM) patients. We previously developed a dose-dense regimen of TMZ in a phase II study (180 mg/m2 from days 1 to 5 every two weeks). A retrospective analysis of patients with macroscopic re...
Main Authors: | Luca Napoleoni, Alessio Cortellini, Katia Cannita, Alessandro Parisi, Antonella Dal Mas, Giuseppe Calvisi, Olga Venditti, Paola Lanfiuti Baldi, Valentina Cocciolone, Alessandro Ricci, Corrado Ficorella |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Bioengineering |
Subjects: | |
Online Access: | https://www.mdpi.com/2306-5354/6/1/11 |
Similar Items
-
Glioblastoma and the significance of MGMT gene methylation
by: Payam Izadpanahi, et al.
Published: (2014-08-01) -
MAXIMIZATION OF DNA DAMAGE TO MGMT(+) EGFR(+) GBM CELLS USING OPTIMAL COMBINATION OF TEMOZOLOMIDE-ANTI EGFR MONOCLONAL ANTIBODY NIMOTUZUMAB
by: M. A. M. Inggas, et al.
Published: (2015-09-01) -
Changes of O<sup>6</sup>-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
by: Jonas Feldheim, et al.
Published: (2019-11-01) -
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
by: Combs Stephanie E, et al.
Published: (2011-09-01) -
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
by: Melguizo Consolación, et al.
Published: (2012-12-01)